ABSTRACT
The
lantibiotic (i.e., lanthionine-containing antibiotic) mersacidin is an
antimicrobial peptide of 20 amino acids which is produced by
Bacillus sp. strain HIL Y-85,54728. Mersacidin inhibits
bacterial cell wall biosynthesis by binding to the precursor molecule
lipid II. The structural gene of mersacidin (mrsA) and the
genes for the enzymes of the biosynthesis pathway, dedicated
transporters, producer self-protection proteins, and regulatory factors
are organized in a biosynthetic gene cluster. For
site-directed mutagenesis of lantibiotics, the engineered genes must be
expressed in an expression system that contains all of the factors
necessary for biosynthesis, export, and producer self-protection. In
order to express engineered mersacidin peptides, a system in which the
engineered gene replaces the wild-type gene on the chromosome was
constructed. To test the expression system, three mutants were
constructed. In S16I mersacidin, the didehydroalanine residue (Dha) at
position 16 was replaced with the Ile residue found in the closely
related lantibiotic actagardine. S16I mersacidin was produced only in
small amounts. The purified peptide had markedly reduced antimicrobial
activity, indicating an essential role for Dha16 in biosynthesis and
biological activity of mersacidin. Similarly, Glu17, which is thought
to be an essential structure in mersacidin, was exchanged for alanine.
E17A mersacidin was obtained in good yields but also showed markedly
reduced activity, thus confirming the importance of the carboxylic acid
function at position 17 in the biological activity of mersacidin.
Finally, the exchange of an aromatic for an aliphatic hydrophobic
residue at position 3 resulted in the mutant peptide F3L mersacidin;
this peptide showed only moderately reduced
activity.